Cormorant Asset Management’s Oncobiologics, Inc. Series B Warrant ONSIZ Stock Holding History

Cormorant Asset Management’s Portfolio ONSIZ Stock Details ONSIZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-416,666	Closed	-$18K	–	64
2018 Q1	$18K	Hold	416,666	–	–	﹤0.01%	50
2017 Q4	$9K	Hold	416,666	–	–	﹤0.01%	51
2017 Q3	$21K	Hold	416,666	–	–	﹤0.01%	50
2017 Q2	$39K	Hold	416,666	–	–	0.01%	70
2017 Q1	$208K	Hold	416,666	–	–	0.03%	73
2016 Q4	$329K	Hold	416,666	–	–	0.04%	72
2016 Q3	$500K	Hold	416,666	–	–	0.06%	74
2016 Q2	$187K	Buy	+416,666	New	+$219K	0.03%	82

Cormorant Asset Management's ONSIZ Position: Q2 2018 in Review

Cormorant Asset Management sold out of Oncobiologics, Inc. Series B Warrant (ONSIZ) in Q2 2018, closing a stake of 416,666 shares — an estimated $18K sold.

Cormorant Asset Management first reported a position in ONSIZ in Q2 2016 and held it in 8 quarters. The position peaked at $500K in Q3 2016. 0 funds tracked by Wall St. Rank hold ONSIZ as of Q2 2018.

Cormorant Asset Management reported no remaining Oncobiologics, Inc. Series B Warrant position as of Q2 2018 after selling out during the quarter.
Cormorant Asset Management sold 416,666 Oncobiologics, Inc. Series B Warrant shares in Q2 2018, an estimated $18K.
Cormorant Asset Management first reported a position in Oncobiologics, Inc. Series B Warrant in Q2 2016 and held it in 8 quarters.
Cormorant Asset Management's Oncobiologics, Inc. Series B Warrant position peaked at $500K in Q3 2016.
0 funds tracked by Wall St. Rank held Oncobiologics, Inc. Series B Warrant as of Q2 2018.

Based on Cormorant Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.